{
    "id": "dbpedia_2900_0",
    "rank": 15,
    "data": {
        "url": "https://www.gesetze-im-internet.de/englisch_amg/englisch_amg.html",
        "read_more_link": "",
        "language": "en",
        "title": "Medicinal Products Act (Arzneimittelgesetz – AMG)",
        "top_image": "",
        "meta_img": "",
        "images": [
            "https://www.gesetze-im-internet.de/img/lay/BfJ_2021_WebSVG_en_en.svg"
        ],
        "movies": [],
        "keywords": [],
        "meta_keywords": [
            ""
        ],
        "tags": null,
        "authors": [],
        "publish_date": null,
        "summary": "",
        "meta_description": "",
        "meta_lang": "",
        "meta_favicon": "",
        "meta_site_name": "",
        "canonical_link": null,
        "text": "Übersetzung durch den Sprachendienst des Bundesministeriums für Gesundheit.\n\nTranslation provided by the Language Service of the Federal Ministry of Health.\n\nStand: Die Übersetzung berücksichtigt die Änderung(en) des Gesetzes durch Artikel 1 des Gesetzes vom 19. Juli 2023 (BGBl. 2023 I Nr. 197)\n\nVersion information: The translation includes the amendment(s) to the Act by Article 1 of the Act of 19 July 2023 (Federal Law Gazette 2023 I no. 197)\n\nTranslations of any materials into languages other than German are intended solely as a convenience to the non-German-reading public. If any questions arise related to the accuracy of the information contained in the translation, please refer to the German version of the document which is the official version of the document. Any discrepancies or differences created in the translation are not binding and have no legal effect for compliance or enforcement purposes.\n\nZur Nutzung dieser Übersetzung lesen Sie bitte den Hinweis unter \"Translations\".\n\nFor conditions governing use of this translation, please see the information provided under \"Translations\".\n\nMedicinal Products Act\n\n(Arzneimittelgesetz – AMG)\n\nFull citation: Medicinal Products Act in the version published on 12 December 2005 (Federal Law Gazette [BGBl.]) Part I p. 3394, last amended by Article 1 of the Act of 19 July 2023 (Federal Law Gazette 2023 I no. 197)\n\nThis version incorporates:\n\n1. the version of the Act promulgated on 12 December 2005 (Federal Law Gazette I p. 3394),\n\n2. Article 12 of the Act of 14 August 2006, which entered into force on 18 August 2006 (Federal Law Gazette I, p. 1869),\n\n3. Article 5 of the Act of 21 December 2006, which entered into force on 28 December 2006 (Federal Law Gazette I p. 3294),\n\n4. Article 2 of the Law of 21 December 2006, which entered into force on 29 December 2006 (Federal Law Gazette I p. 3367),\n\n5. Article 30 of the Act of 26 March 2007, which partially entered into force on 1 April 2007 and partially on 1 January 2009 (Federal Law Gazette I p. 378),\n\n6. Article 2 of the Act of 14 June 2007, which entered into force on 30 June 2007 (Federal Law Gazette I p. 1066),\n\n7. Article 2 of the Act of 20 July 2007, which entered into force on 1 August 2007 (Federal Law Gazette I p. 1574),\n\n8. Article 2 of the Act of 24 October 2007, which entered into force on 1 November 2007 (Federal Law Gazette I p. 2510),\n\n9. Article 9 (1) of the Law of 23 November 2007, which entered into force on 1 January 2008 (Federal Law Gazette I p. 2614),\n\n10. Article 2 of the Act of 15 July 2009, which entered into force on 21 July 2009 (Federal Law Gazette I p. 1801),\n\n11. Article 1 of the Act of 17 July 2009, which entered into force on 23 July 2009 (Federal Law Gazette I, p. 1990, p. 3578),\n\n12. Article 1 of the Ordinance of 28 September 2009, which entered into force on 3 October 2009 (Federal Law Gazette I p. 3172),\n\n13. Article 1 of the Ordinance of 29 November 2010, which entered into force on 9 December 2010 (Federal Law Gazette I p. 1752),\n\n14. Article 7 of the Act of 22 December 2010, which entered into force on 1 January 2011 (Federal Law Gazette I p. 2262),\n\n15. Article 1 of the Act of 25 May 2011, which entered into force on 31 May 2011 (Federal Law Gazette I, p. 946),\n\n16. Article 1 of the Ordinance of 19 July 2011, which entered into force on 26 July 2011 (Federal Law Gazette I p. 1398),\n\n17. Article 13 of the Law of 22 December 2011 which entered into force on 29 December 2011 (Federal Law Gazette I p. 2983),\n\n18. Article 1 of the Ordinance of 16 July 2012, which entered into force on 24 July 2012 (Federal Law Gazette I p. 1534),\n\n19. Articles 1 and 2 of the Act of 19 October 2012, which entered into force on 26 October 2012 (Federal Law Gazette I p. 2192),\n\n20. Article 4 of the Act of 21 March 2013, which entered into force on 29 March 2013 (Federal Law Gazette I p. 566),\n\n21. Article 1 of the Ordinance of 25 March 2013, which entered into force on 9 April 2013 (Federal Law Gazette I p. 627),\n\n22. Article 5 (1) of the Act of 20 April 2013, which entered into force on 25 April 2013 (Federal Law Gazette I p. 868),\n\n23. Article 1 of the Ordinance of 24 June 2013, which entered into force on 29 June 2013 (Federal Law Gazette I p. 1687),\n\n24. Article 2 of the Act of 15 July 2013, which entered into force on 1 August 2013 (Federal Law Gazette I p. 2420),\n\n25. Article 1 of the Ordinance of 12 July 2013, which entered into force on 19 July 2013 (Federal Law Gazette I p. 2439),\n\n26. Article 2 of the Act of 23 July 2013, which entered into force on 1 September 2013 (Federal Law Gazette I p. 2565),\n\n27. Article 1 of the Act of 7 August 2013, which entered into force on 13 August 2013 (Federal Law Gazette I, p. 3108),\n\n28. Article 2 (24) and Article 4 (11) of the Act of 7 August 2013 which entered into force on 15 August 2013 (Federal Law Gazette I p. 3154),\n\n29. Article 1 of the Act of 10 October 2013, which entered into force on 1 April 2014 (Federal Law Gazette I, p. 3813),\n\n30. Article 2a of the Act of 27 March 2014, which entered into force on 1 April 2014 (Federal Law Gazette I p. 261),\n\n31. Article 3 of the Act of 17 December 2014, which entered into force on 24 December 2014 (Federal Law Gazette I p. 2222),\n\n32. Article 52 of the Ordinance of 31 August 2015, which entered into force on 8 September 2015 (Federal Law Gazette I p. 1474),\n\n33. Article 1 of the Ordinance of 2 September 2015, which entered into force on 26 September 2015 (Federal Law Gazette I p. 1571),\n\n34. Articles 2 and 3 of the Act of 10 December 2015, which entered into force on 18 December 2015 (Federal Law Gazette I p. 2210),\n\n35. Article 3 of the Act of 4 April 2016, which entered into force on 20 May 2016 (Federal Law Gazette I p. 569),\n\n36. Article 4 (11) of the Act of 18 July 2016, which enters into force on 1 October 2021 (Federal Law Gazette I p. 1666),\n\n37. Article 1 of the Act of 21 November 2016, which entered into force on 26 November 2016 (Federal Law Gazette I, p. 2623),\n\n38. Article 6b of the Act of 19 December 2016, which entered into force on 1 January 2017 (Federal Law Gazette I p. 2986),\n\n39. Article 1, which entered into force on 24 December 2016, as well as Article 2, which entered into force on 27 January 2022 of the Act of 20 December 2016 (Federal Law Gazette I p. 3048),\n\n40. Article 1 of the Ordinance of 10 March 2017, which entered into force on 16 March 2017 (Federal Law Gazette I p. 456),\n\n41. Article 45 of the Act of 29 March 2017, which entered into force on 5 April 2017 (Federal Law Gazette I p. 626),\n\n42. Article 6 (9) of the Act of 13 April 2017, which entered into force on 1 July 2017 (Federal Law Gazette I p. 872),\n\n43. Article 5 of the Act of 4 May 2017, which entered into force on 13 May 2017 (Federal Law Gazette I, p. 1050),\n\n44. Article 2 of the Act of 17 July 2017, which entered into force on 22 July 2017 (Federal Law Gazette I p. 2421),\n\n45. Article 1 of the Act of 18 July 2017, which entered into force on 29 July 2017 (Federal Law Gazette I, p. 2757),\n\n46. Article 1 of the Ordinance of 17 April 2019, which entered into force on 4 May 2019 (Federal Law Gazette I p. 537),\n\n47. Article 11 of the Act of 6 May 2019, which entered into force on 11 May 2019 (Federal Law Gazette I p. 646),\n\n48. Articles 1 and 2 of the Act of 9 August 2019, which entered into force on 16 August 2019 (Federal Law Gazette I p. 1202),\n\n49. Article 18 of the Act of 20 November 2019, which entered into force on 26 November 2019 (Federal Law Gazette I p. 1626),\n\n50. Article 3c of the Act of 10 February 2020, which entered into force on 1 March 2020 (Federal Law Gazette I p. 148),\n\n51. Article 0 of the Act of 22 March 2020, which entered into force on 1 April 2020 (Federal Law Gazette I p. 604),\n\n52. Article 7 of the Act of 28 April 2020, which entered into force on 23 May 2020 and Article 16a (3) of the Act of 28 April 2020, which entered into force on 23 and 26 May 2020 (Federal Law Gazette I p. 960), as well as Article 8 of the Act of 28 April 2020, which entered into force on 26 May 2022 (Federal Law Gazette I p. 960),\n\n53. Article 94 of the Ordinance of 19 June 2020, which entered into force on 27 June 2020 (Federal Law Gazette I p. 1328),\n\n54. Article 2 (1) of the Act of 25 June 2020, which entered into force on 30 June 2020 (Federal Law Gazette I p. 1474),\n\n55. Article 2b of the Act of 18 November 2020, which entered into force on 19 November 2020 (Federal Law Gazette I p. 2397),\n\n56. Article 5 of the Law of 9 December 2020, which entered into force on 15 December 2020 (Federal Law Gazette I p. 2870),\n\n57. Article 7 of the Act of 21 May 2021, which entered into force on 26 May 2021 (Federal Law Gazette I, p. 1087), as well as Article 8 of the Act of 12 May 2021, which entered into force on 26 May 2022 (Federal Law Gazette I p. 1087),\n\n58. Article 1 of the Ordinance of 19 May 2021, which entered into force on 28 May 2021 (Federal Law Gazette I p. 1164),\n\n59. Article 9 of the Act of 3 June 2021, which entered into force on 9 June 2021 (Federal Law Gazette I p. 1309),\n\n60. Article 10 (4) of the Act of 27 July 2021, which entered into force on 10 August 2021 (Federal Law Gazette I p. 3274),\n\n61. Article 10 of the Act of 10 August 2021, which entered into force on 1 January 2024 (Federal Law Gazette I p. 3436),\n\n62. Article 1 of the Act of 10 August 2021, which entered into force on 1 November 2021 (Federal Law Gazette I, p. 3519),\n\n63. Articles 2 and 3 of the Act of 27 September 2021, which entered into force on 27 and 28 January 2022 respectively (Federal Law Gazette I p. 4530),\n\n64. Article 14 of the Act of 24 June 2022, which entered into force on 1 January 2023 (Federal Law Gazette I p. 959),\n\n65. Article 1a of the Act of 7 November 2022, which entered into force on 12 November 2022 (Federal Law Gazette I p. 1990),\n\n66. Article 2 (2) of the Act of 20 December 2022, which entered into force on 1 January 2023 (Federal Law Gazette I p. 2752),\n\n67. Article 8c of the Act of 20 December 2022, which entered into force on 29 December 2022 (Federal Law Gazette I p. 2793),\n\n68. Article 1 of the Act of 19 July 2023, which entered into force on 27 July 2023 (Federal Law Gazette 2023 I no. 197).\n\ntable of contents\n\nDivision 1\n\nPurpose of the Act and definition of terms, scope\n\ntable of contents\n\nSection 1\n\nPurpose of the Act\n\nIt is the purpose of this Act to guarantee safety in respect of the trade in medicinal products, ensuring in particular the quality, efficacy and safety of medicinal products in accordance with the following provisions, in the interest of furnishing the population with a proper supply of medicinal products.\n\ntable of contents\n\nSection 2\n\nThe term ‘medicinal product’\n\n(1) Medicinal products within the meaning of this Act are medicinal products that are intended for administration to human beings. These comprise substances or preparations made from substances that:\n\n1. are intended for use in or on the human body and are intended for use as remedies with properties for the curing, alleviating or preventing of human diseases or disease symptoms, or\n\n2. can be used in or on the human body or can be administered to a human being, either:\n\na) to restore, correct or influence the physiological functions through a pharmacological, immunological or metabolic effect, or\n\nb) to make a medical diagnosis.\n\n(2) Medicinal products comprise objects that contain a medicinal product pursuant to subsection (1) or to the surface of which a medicinal product specified in subsection (1) is applied and that are intended to come into either temporary or permanent contact with the human body.\n\n(3) Medicinal products within the meaning of this Act are not:\n\n1. veterinary medicinal products within the meaning of Article 4 no. 1 of Regulation (EU) 2019/6 of the European Parliament and of the Council of 11 December 2018 on veterinary medicinal products and repealing Directive 2001/82/EC (OJ L 4, 7.1.2019, p. 43; L 163, 20.6.2019, p. 112; L 326, 8.10.2020, p. 15; L 241, 8.7.2021, p. 17) in the latest applicable version, as well as veterinary medicinal products pursuant to section 3 of the Veterinary Medicinal Products Act (Tierarzneimittelgesetz),\n\n2. foods within the meaning of Article 2 of Regulation (EC) No. 178/2002 of the European Parliament and the Council of 28 January 2002 laying down the general principles and requirements of food law, establishing the European Food Safety Authority and laying down procedures in matters of food safety (OJ. L 31 of 1.2.2002, p. 1), last amended by Regulation (EU) 2019/1381 (OJ L 231 of 6.9.2019, p. 1),\n\n3. cosmetic products within the meaning of Article 2 (1) point (a) also in conjunction with paragraph 2 of Regulation (EC) No. 1223/2009 of the European Parliament and of the Council of 30 November 2009 on cosmetic products (OJ L 342 of 22.12.2009, p. 59,L 318 of 15.11.2012, p. 74; L 72 of 15.3.2013, p. 16; L 142 of 29.5.2013, p.10; L 254 of 28.8.2014, p. 39; L 17 of 21.1.2017, p. 52; L 326 of 9.12.2017, p. 55; L 183 of 19.7.2018, p.27; L 324 of 13.12.2019, p.80; L 76 of 12.3.2020, p. 36), last amended by Regulation (EU) 2019/1966 (OJ L 307 of 28.11.2019, p. 15),\n\n4. products as defined in section 2 (1) of the Tobacco Products Act (Tabakerzeugnisgesetz),\n\n5. biocidal products according to Article 3 (1) point (a) of Regulation (EU) No. 528/2012 of 22 May 2012 of the European Parliament and of the Council concerning the making available on the market and use of biocidal products (OJ L 167, 27.6.2012, p. 1; OJ L 303, 20.11.2015, p. 109; L 305, 21.11.2015, p. 55; L 280 of 28.10.2017, p .57), last amended by Commission Delegated Regulation (EU) 2021/407 (OJ L 81 of 9.3.2021, p. 15),\n\n6. (repealed)\n\n7. medical devices and accessories for medical devices within the meaning of Article 2 nos. 1 and 2 of Regulation (EU) 2017/745 of the European Parliament and of the Council of 5 April 2017 on medical devices, amending Directive 2001/83/EC, Regulation (EC) No 178/2002 and Regulation (EC) No 1223/2009 and repealing Council Directives 90/385/EEC and 93/42/EEC (OJ L 117, 5.5.2017, p.1, L 117 of 3.5.2019, p. 9; L 334 of 27.12.2019, p. 165), amended by Regulation (EU) 2020/561 (OJ L 130 of 24.4.2020, p. 18), in the version in force in each case and within the meaning of Article 2 nos. 2 and 4 of Regulation (EU) 2017/746 of the European Parliament and of the Council of 5 April 2017 on in-vitro diagnostics and repealing Council Directive 98/79/EG and Commission Decision 2010/227/EU (OJ L 117, 5.5.2017, p.176; OJ L 117, 3.5.2019, p. 11, L 334 of 27.12. 2019, p. 167) in the latest applicable version, unless they are medicinal products within the meaning of subsection (1) no. 2 letter b,\n\n8. organs within the meaning of section 1a no. 1 of the Transplantation Act (Transplantationsgesetz) if they are intended for transplanting to human beings.\n\n(3a) Medicinal products are also products that are, or contain, substances or preparations made from substances that, when all of the product’s properties are taken into account, fall under the definition contained in subsection (1) and, at the same time, can fall under the definition of a ‘product’ pursuant to subsection (3).\n\n(4) As long as a product is authorised or registered as a medicinal product pursuant to this Act, or is exempted from the need for authorisation or registration by ordinance, such product is considered to be a medicinal product. A product is not considered a medicinal product if its authorisation or registration has been rejected by the competent higher federal authority on the grounds that it is not a medicinal product.\n\ntable of contents\n\nSection 3\n\nThe term ‘substance’\n\nFor the purpose of this Act, substances are:\n\n1. chemical elements and chemical compounds as well as their naturally occurring mixtures and solutions,\n\n2. plants, parts of plants and plant constituents, algae, fungi and lichen, whether in their processed or crude state,\n\n3. the bodies of animals, including those of living animals, as well as body parts, body constituents and metabolic products of human beings or animals, whether in their processed or crude state,\n\n4. micro-organisms, including viruses, as well as their constituents or metabolic products.\n\ntable of contents\n\nSection 4\n\nDefinition of additional terms\n\n(1) Finished medicinal products are medicinal products that are manufactured beforehand and placed on the market in packaging intended for distribution to the consumer, or other medicinal products intended for distribution to the consumer in the preparation of which any form of industrial process is used, or medicinal products that are produced commercially, except in pharmacies. Finished medicinal products are not intermediate products intended for further processing by a manufacturer.\n\n(2) Blood preparations are medicinal products that are or contain, as active substances, stored blood, plasma or serum obtained from blood, blood components or preparations made from blood components.\n\n(3) Sera are medicinal products within the meaning of section 2 (1) that contain antibodies, fragments of antibodies or fusion proteins with a functional antibody component as their active substance and are used because of this active substance. Sera are not considered blood preparations as defined in subsection (2) or as tissue preparations as defined in subsection (30).\n\n(4) Vaccines are medicinal products within the meaning of section 2 (1) that contain antigens or recombinant nucleic acids and are intended for human use to produce specific antitoxins and protective agents and, insofar as they contain recombinant nucleic acids, are intended exclusively to prevent or treat infectious diseases.\n\n(5) Allergens are medicinal products within the meaning of section 2 (1) that contain antigens or haptens and are intended for human use to diagnose specific antitoxins or protective agents (test allergens), or contain substances that are used to achieve an antigen-specific reduction of a specific immunological over-sensitivity (therapeutic allergens).\n\n(6) (repealed)\n\n(7) (repealed)\n\n(8) Radiopharmaceuticals are medicinal products that are or contain radioactive substances and spontaneously emit ionising radiation and are intended to be used on account of these properties; radionuclides (precursors) that are manufactured for the radio labelling of other substances prior to administration, as well as systems incorporating a fixed mother radionuclide that produces a daughter radionuclide (generator) intended for use in the manufacture of radiopharmaceuticals, are also regarded as radiopharmaceuticals.\n\n(9) Advanced therapy medicinal products are gene therapy medicinal products, somatic cell therapy medicinal products or tissue engineered products pursuant to Article 2, paragraph 1, point (a) of Regulation (EC) No. 1394/2007 of the European Parliament and the Council of 13th November 2007 on advanced therapy medicinal products and amending Directive 2001/83/EC and Regulation (EC) No. 726/2004 (OJ L 324 of 10.12.2007, p. 121); L 87 of 31.3.2009, p. 174), last amended by Regulation (EU) 2019/1243 (OJ L 198 of 25.07.2019, p. 241).\n\n(10) (repealed)\n\n(11) (repealed)\n\n(12) (repealed)\n\n(13) Adverse reactions are noxious and unintended reactions to the medicinal product. Serious adverse reactions are adverse reactions that are fatal or life-threatening, require hospitalisation or the prolongation of existing hospitalisation, or lead to persistent or significant disability, incapacity, congenital anomalies or birth defects. Unexpected adverse reactions are adverse reactions the type, severity or consequences of which differ from the medicinal product’s expert information.\n\n(14) Manufacturing is the producing, preparing, formulating, treating or processing, filling as well as decanting, packaging, labelling and release of medicinal products; manufacturing is not the mixing of finished medicinal products with feeding stuffs by the animal keeper for immediate feeding to the animals kept by him/her.\n\n(15) Quality is the nature of a medicinal product, determined by identity, content, purity and other chemical, physical and biological properties or by the manufacturing procedure.\n\n(16) A batch is the quantity of a medicinal product produced from the same amount of starting material in a standard manufacturing process or, in the case of a continuous manufacturing procedure, within a specific period of time.\n\n(17) Placing on the market is the keeping in stock for sale or for other forms of supply, the exhibiting and offering for sale and the distribution to others.\n\n(18) In the case of medicinal products requiring a marketing authorisation or registration, the pharmaceutical entrepreneur is the holder of the marketing authorisation or registration. The pharmaceutical entrepreneur is also any person who places medicinal products by parallel distribution or otherwise on the market under his/her own name, with the exception of the cases provided for in section 9 (1), sentence 2.\n\n(19) Active substances are substances that are intended for use as medically active constituents in the manufacture of medicinal products or which, through their use in the manufacture of medicinal products, are intended to become medically active constituents.\n\n(20) An excipient is any component of a medicinal product, with the exception of the active substance and the packaging material.\n\n(21) Xenogenic medicinal products are medicinal products that are or contain living animal tissues or cells and are intended for use in or on humans.\n\n(22) Wholesaling of medicinal products is any professional or commercial activity for trading purposes that consists of procuring, storing, selling or exporting medicinal products, with the exception of the sale of medicinal products to customers other than doctors, dentists, veterinarians or hospitals.\n\n(22a) Brokering of medicinal products is any professional or commercial activity by persons who, without conducting wholesale distribution, independently and on behalf of another, trade in medicinal products without obtaining actual power of disposal over the medicinal products.\n\n(23) A clinical trial is a trial within the meaning of Article 2 (2) (2) of Regulation (EU) No. 536/2014 of the European Parliament and of the Council of 16 April 2014 on clinical trials on medicinal products for human use, and repealing Directive 2001/20/EC (OJ L 158 of 27.5.2014, p. 1, L 311 of 17.11.2016, p. 25). A non-interventional study within the meaning of Article 2 (2) (4) of Regulation (EU) No. 536/2014 is not a clinical trial.\n\n(24) A sponsor is a person, undertaking, institution or organisation within the meaning of Article 2 (2) (14) of Regulation (EU) No. 536/2014.\n\n(25) An investigator is a person within the meaning of Article 2 (2) (15) of Regulation (EU) No. 536/2014. A principal investigator is a person within the meaning of Article 2 (2) (16) of Regulation (EU) No. 536/2014.\n\n(26) A homeopathic medicinal product is any medicinal product prepared in accordance with a homeopathic manufacturing procedure described in the European Pharmacopoeia or, in absence thereof, in the pharmacopoeias currently used officially in the EU Member States. A homeopathic medicinal product can also contain several active substances.\n\n(27) A risk linked to the use of a medicinal product is:\n\na) any risk to patient or public health linked to the quality, safety or efficacy of the medicinal product,\n\nb) any risk of adverse effects on the environment.\n\n(29) Herbal medicinal products are medicinal products that exclusively contain, as active substances, either one or more herbal substances, one or more herbal preparations, or one or more such herbal substances in combination with one or more such herbal preparations.\n\n(30) Tissue preparations are medicinal products that are tissues within the meaning of section 1a no. 4 of the Transplantation Act or are manufactured from such tissues. Human sperm and egg cells (germ cells), as well as impregnated egg cells and embryos are neither medicinal products nor tissue preparations.\n\n(30a) The ‘Single European Code’ or ‘SEC’ is the unique identifier for all tissues and tissue preparations that are distributed within the European Union, as specified in Annex VII of Commission Directive 2006/86/EC of 24 October 2006 implementing Directive 2004/23/EC of the European Parliament and of the Council as regards traceability requirements, notification of serious adverse reactions and events and certain technical requirements for the coding, processing, preservation, storage and distribution of human tissues and cells (OJ L 294 of 25.10.2006, p. 32), last amended by (EU) Directive 2015/565 (OJ L 93 of 9.4.2015, p. 43).\n\n(30b) The EU tissue establishment code is the unique identifier for tissue establishments in the European Union. Within the purview of this Act, it applies to all facilities that conduct activities that require a permit, involving tissues, tissue preparations, haematopoietic stem cells, or stem cell preparations derived from peripheral blood or from umbilical cord blood. Pursuant to Annex VII of Directive 2006/86/EC, the EU tissue establishment code consists of an ISO country code and the tissue establishment number set out in the EU Tissue Establishment Compendium.\n\n(30c) The EU Compendium of Tissue Establishments is the register of all tissue establishments that are approved, licensed, designated or authorised by the Member States’ competent authorities and which contains the information on these tissue establishments pursuant to Annex VIII of Directive 2006/86/EC in the latest applicable version. Within the purview of this Act, the register applies to all facilities that conduct activities requiring a permit involving tissues, tissue preparations or haematopoietic stem cells, or stem cell preparations derived from peripheral blood or from umbilical cord blood.\n\n(30d) The EU Tissue and Cell Product Compendium is the register of all the types of tissue, tissue preparations or haematopoietic stem cells, or stem cell preparations derived from peripheral blood or umbilical cord blood, circulating in the European Union, with the corresponding product code.\n\n(31) Reconstitution of a finished medicinal product is the conversion of the medicinal product into its usable form immediately prior to its use according to the specifications contained in the package leaflet or, within the framework of the clinical trial, in accordance with the trial protocol.\n\n(32) Introduction is any type of shipment into, through or from the purview of this Act. Import is the conveyance of products that fall under the Medicinal Products Act from third countries that are not States Party to the Agreement on the European Economic Area for free circulation. Products pursuant to sentence 2 are considered to be imported if they have been brought into the economic system in contravention of customs regulations. Export is any introduction into third countries that are not States Party to the Agreement on the European Economic Area.\n\n(33) An anthroposophic medicinal product is a medicinal product that has been developed according to the anthroposophic understanding of human beings and nature, according to a European Pharmacopoeia or, in the absence thereof, in accordance with a homeopathic manufacturing practice described in the pharmacopoeias currently used officially in the EU Member States, or according to a special anthroposophic manufacturing procedure, and which is intended for use according to the principles of the anthroposophic understanding of human beings and nature.\n\n(34) A post-authorisation safety study is any study of an authorised medicinal product that is conducted to identify, characterise or quantify a safety risk, to confirm a medicinal product’s safety profile or to measure the effectiveness of risk management measures.\n\n(35) (repealed)\n\n(36) The risk management system comprises activities in the field of pharmacovigilance and measures that are intended to identify, characterise, avoid or minimise risks associated with a medicinal product; this includes the assessment of the effectiveness of such activities and measures.\n\n(37) The risk management plan is a detailed description of the risk management system.\n\n(38) The pharmacovigilance system is a system used by the marketing authorisation holder and the competent higher federal authority to fulfil especially the tasks and obligations listed in Division 10 and which serves the purpose of post-marketing surveillance and the detection of any changes in the risk-benefit profile.\n\n(39) The pharmacovigilance master file is a detailed description of the pharmacovigilance system used by the marketing authorisation holder with respect to one or more authorised medicinal products.\n\n(40) A falsified medicinal product is any medicinal product with a false representation of:\n\n1. its identity, including its packaging and labelling, its name or its composition as regards one or several of its constituents including excipients and the strength of those ingredients;\n\n2. its source, including its manufacturer, its country of manufacture, its country of origin or its marketing authorisation holder; or\n\n3. distribution channels described in the related records and documents.\n\n(41) A falsified active substance is an active substance for which the labelling on the container does not correspond to the actual content or the accompanying documents fail to reflect all of the manufacturers involved or the real channels of distribution.\n\n(42) The EU portal is the portal for the submission of data and information relating to clinical trials that is set up and maintained at EU level in accordance with Article 80 of Regulation (EU) No. 536/2014.\n\ntable of contents\n\nSection 4a\n\nExceptions to the scope of this Act\n\nThis Act does not apply to tissues that are removed from a person in order to reinsert them without changing their material structure into the same person in one and the same treatment procedure.\n\ntable of contents\n\nSection 4b\n\nSpecial provisions governing advanced therapy medicinal products\n\n(1) In the case of advanced therapy medicinal products that are:\n\n1. prescribed by a doctor as an individual preparation for an individual patient,\n\n2. prepared on a non-routine basis according to specific quality standards, and\n\n3. used in a specialised facility for health care under the professional responsibility of a doctor,\n\nwithin the purview of this Act, Division 4 with the exception of section 33 and Division 7 of this Act do not apply. The remaining provisions of the Act, as well as Article 14 (1) and Article 15 (1) to (6) of Regulation (EC) No. 1394/2007, apply accordingly with the proviso that the official tasks and powers laid down therein are assumed by the competent authority or the competent higher federal authority in keeping with the tasks entrusted to them by this Act and the holder of the authorisation pursuant to subsection (3) sentence 1 takes the place of the marketing authorisation holder pursuant to this Act or the marketing authorisation holder pursuant to Regulation (EC) No. 1394/2007.\n\n(2) Prepared on a non-routine basis pursuant to subsection (1) sentence 1 no. 2 are, in particular, medicinal products:\n\n1. that are manufactured and used in such small quantities that it is not to be expected that sufficient clinical experience can be collected for a comprehensive evaluation of the medicinal product, or\n\n2. that have not yet been manufactured and used in sufficient quantities so that it has not yet been possible to obtain the necessary data to enable a comprehensive assessment.\n\n(3) Medicinal products pursuant to subsection (1) sentence 1 may only be supplied to others if they have been approved by the competent higher federal authority. Section 21a (2) sentence 1, subsections (3) to (6) and (8) apply accordingly. In addition to the information and documents pursuant to section 21a (2) sentence 1, the application for approval are to be accompanied by the following information and documents:\n\n1. information on the specialised healthcare facility in which the medicinal product is to be used,\n\n2. the number of planned administrations or patients per year,\n\n3. information on dosage,\n\n4. information on the risk management plan containing a description of the risk management system, which the applicant will introduce for the medicinal product in question, together with a summary of the risk management plan and the risk management system, and\n\n5. in the case of advanced therapy medicinal products consisting of a genetically modified organism or a combination of genetically modified organisms or containing such organisms, also the technical documents pursuant to Annexes III A, III B and IV of Directive 2001/18/EC of the European Parliament and of the Council of 12 March 2001 on the deliberate release into the environment of genetically modified organisms and repealing Council Directive 90/220/EEC (OJ L 106 of 17.4.2001, p. 1), last amended by Regulation (EU) 2019/1381 (OJ L 231 of 6.9.2019, p. 1), as well as information obtained from an environmental impact assessment conducted according to Annex II of Directive 2001/18/EC, pursuant to Annex II point (D) of Directive 2001/18/EC.\n\nSection 22 (2) sentence 1 no. 5, subsections (4) and (7) sentence 1 apply accordingly.\n\n(4) In the case of advanced therapy medicinal products consisting of a genetically modified organism or a combination of genetically modified organisms or containing such organisms, the competent higher federal authority decides on the application for approval in consultation with the Federal Agency for Consumer Protection and Food Safety. The approval by the competent higher federal authority for the dispensing of medicinal products to other persons pursuant to sentence 1 also includes the authorisation for placing on the market the genetically modified organisms from which the medicinal product pursuant to sentence 1 is manufactured or that contain it. Approval may only be granted if:\n\n1. an environmental impact assessment was conducted according to the basic principles contained in Annex II of Directive 2001/18/EC and based on the information according to Annexes III and IV of Directive 2001/18/EC, and\n\n2. according to the latest standards prevailing in science, unjustifiable harmful effects on the health of third parties and the environment are not to be expected.\n\n(5) If the necessary information and documents pursuant to section 21a (2) sentence 1 no. 8 cannot be submitted, the applicant can submit information and documents regarding the mode of action, the anticipated effect and possible risks.\n\n(6) Approval can be issued for a limited period of time.\n\n(7) The holder of the approval must inform the competent higher federal authority, at specific intervals stipulated by the latter by means of an ordinance, about the scale of manufacture and about the data for the comprehensive assessment of the medicinal product. The approval is to be withdrawn if it subsequently becomes known that one of the prerequisites pursuant to subsection (1) sentence 1 had not existed. The approval is to be revoked if one of the prerequisites pursuant to subsection (1) sentence 1 no longer exists.\n\n(8) The applicant must notify the competent higher federal authority forthwith, enclosing the corresponding documents, in the event of any changes in the information or documents that were enclosed with the application for approval. Subsequent to the approval, sentence 1 applies accordingly to the holder of the approval. The latter is required to inform the competent higher federal authority of new or changed risks or of changes in the medicinal product’s risk-benefit balance. In the case of advanced therapy medicinal products consisting of a genetically modified organism or a combination of genetically modified organisms or containing such organisms, the applicant must notify the competent higher federal authority forthwith, enclosing the corresponding documents, if he/she becomes aware of new information on risks to the health of non-affected persons or the environment. Following approval, sentence 4 applies accordingly to the holder of the approval. Section 29 (1a), (1d) and (2) apply accordingly.\n\n(9) The following changes may be made only if the competent higher federal authority has granted its approval:\n\n1. a change in the information on the dosage, the type or the duration of the administration, or on the therapeutic indications if it does not concern an addition or modification of an indication that is to be classified under another area of therapy,\n\n2. a limitation of the contra-indications, adverse reactions or interactions with other medicinal products or other substances,\n\n3. a change in either the type or quantity of the excipients, or in the quantity of active substances,\n\n4. a change in the pharmaceutical form into a pharmaceutical form that is compatible with the approved pharmaceutical form,\n\n5. a change in the manufacturing or test procedures, including the information pursuant to section 21a (2) sentence 1 no. 5,\n\n6. a change in the conditions for storage and the shelf life, or\n\n7. in the case of advanced therapy medicinal products consisting of a genetically modified organism or a combination of genetically modified organisms or containing such organisms, a change that is capable of modifying the risk assessment for the health of non-affected persons or the environment.\n\nThe decision on the application for approval must be taken within three months. Subsection (4) and section 27 (2) apply accordingly.\n\n(10) By way of derogation from subsection (9), a new approval pursuant to subsection (3) is to be applied for in the following cases:\n\n1. where the therapeutic indications are broadened, insofar as a change pursuant to subsection (9) sentence 1 no. 1 is not concerned,\n\n2. where there is a change in the composition of the active substances in terms of the type,\n\n3. where there is a change in the pharmaceutical form, insofar as a change pursuant to subsection (9) sentence 1 no. 4 is not concerned,\n\nThe competent higher federal authority decides on the obligation to obtain an approval pursuant to sentence 1.\n\n(11) Enquiries about the obligation to obtain an approval for an advanced therapy medicinal product are decided by the competent authority in consultation with the competent higher federal authority. Section 21 (4) applies accordingly.\n\ntable of contents\n\nDivision 2\n\nRequirements on medicinal products\n\ntable of contents\n\nSection 5\n\nProhibition of unsafe medicinal products\n\n(1) The placing on the market or the use of unsafe medicinal products on another human being is prohibited.\n\n(2) Medicinal products are considered unsafe if, according to the current level of scientific knowledge, there is sufficient reason to suspect that, when used in accordance with their intended purpose, they have harmful effects that exceed the limits considered tolerable in the light of current medical knowledge.\n\ntable of contents\n\nSection 6\n\nProhibitions to protect health, power to issue ordinances\n\n(1) It is prohibited to manufacture, place on the market, or administer medicinal products if in manufacturing the medicinal product a provision provided for in an ordinance pursuant to subsection (2) on the use of substances, preparations from substances or objects contained in the Annex is contravened.\n\n(2) The Federal Ministry of Health (the Federal Ministry) is hereby empowered to stipulate, restrict or prohibit, by ordinance subject to the approval of the Bundesrat, the use of the substances, preparations from substances or objects named in the Annex in the manufacture of medicinal products insofar as this is deemed necessary to ward off risks to human health (risk prevention) or to prevent medicinal products from posing a direct or indirect hazard to human health.\n\n(3) The Federal Ministry is hereby empowered to issue ordinances, subject to the approval of the Bundesrat, adding additional substances, preparations from substances or objects to the Annex, insofar as this is deemed necessary in the interest of risk prevention or in order to prevent medicinal products from posing a direct or indirect hazard to human health. By ordinance pursuant to sentence 1, substances, preparations from substances or objects are to be removed from Annex 1 if the prerequisites contained in sentence 1 are no longer met.\n\n(4) The ordinances pursuant to subsections (2) and (3) are issued in agreement with the Federal Ministry for the Environment, Nature Conservation, Building and Nuclear Safety in the case of radiopharmaceuticals and medicinal products in the manufacture of which ionising radiation is used.\n\ntable of contents\n\nSection 6a\n\n(repealed)\n\ntable of contents\n\nSection 7\n\nRadiopharmaceuticals and medicinal products treated with ionising radiation\n\n(1) The placing on the market of radiopharmaceuticals or medicinal products in the manufacture of which ionising radiation has been used is forbidden, unless the authorisation to do so has been granted by ordinance according to subsection (2).\n\n(2) The Federal Ministry is hereby empowered to authorise, in agreement with the Federal Ministry for the Environment, Nature Conservation and Nuclear Safety, by means of an ordinance subject to the approval of the Bundesrat, the placing of radiopharmaceuticals on the market or the use of ionising radiation in the manufacture of medicinal products insofar as this is deemed, according to the current level of scientific knowledge, to be justified for medical purposes and insofar as it does not compromise human health. The ordinance may prescribe the channel of distribution for the medicinal products and specify that certain data concerning their radioactivity are to appear on the container, the outer packaging and the package leaflet.\n\ntable of contents\n\nSection 8\n\nProhibitions to prevent deception\n\n(1) It is prohibited to manufacture or place on the market medicinal products or active substances, which:\n\n1. by deviating from recognised pharmaceutical rules, are of considerably reduced quality, or\n\n1a. (repealed)\n\n2. bear a misleading name, information or presentation. Deception exists, in particular, in cases where:\n\na) claims are made to the effect that certain medicinal products have a therapeutic efficacy or effects that they do not possess or that active substances exhibit an activity that they do not,\n\nb) the erroneous impression is given that success can be expected with certainty or that no harmful effects occur when the medicinal product is used in accordance with its intended purpose or over an extended period of time;\n\nc) names, specifications or presentations, which have an influence on the assessment of the medicinal product or active substance, are employed to mislead others with regard to its quality.\n\n(2) It is prohibited to manufacture, place on the market or otherwise trade in falsified medicinal products or falsified active substances.\n\n(3) It is prohibited to manufacture or place medicinal products on the market past the expiry date.\n\ntable of contents\n\nSection 9\n\nThe party responsible for placing on the market\n\n(1) Medicinal products that are placed on the market within the purview of this Act must carry the name or the company and the address of the pharmaceutical entrepreneur. This does not apply to medicinal products that are intended for clinical trials.\n\n(2) Within the purview of this Act, medicinal products may only be placed on the market by a pharmaceutical entrepreneur whose registered place of business is situated within the purview of this Act, in another Member State of the European Union or another State Party to the Agreement on the European Economic Area. If the pharmaceutical entrepreneur appoints a local representative, this does not release him/her from his/her legal responsibility.\n\ntable of contents\n\nSection 10\n\nLabelling\n\n(1) Finished medicinal products that are not intended for clinical trials and are not exempted from the obligation to obtain a marketing authorisation pursuant to section 21 (2) no. 1a, 1b or 3 may only be placed on the market within the purview of this Act provided that the following information is displayed on the containers and, where used, on the outer packaging in easily legible and indelible characters, in readily comprehensible German and pursuant to the details referred to in section 11a:\n\n1. the name or the company and the address of the pharmaceutical entrepreneur and, if available, the name of the local representative appointed by him,\n\n2. the name of the medicinal product, followed by details of the strength and pharmaceutical form and, if applicable, the indication that it is intended for administration to babies, children or adults unless this information is already included in the name; if the medicinal product contains up to three active substances, the international non-proprietary name (INN) must be stated or, if one does not exist, the common name; this does not apply if the name contains the name of the active substance pursuant to no. 8,\n\n3. the marketing authorisation number, with the abbreviation ‘Zul.-Nr’,\n\n4. the batch identification, if the medicinal product is placed on the market in batches, with the abbreviation ‘Ch.-B.’; if it cannot be placed on the market in batches, the date of manufacture,\n\n5. the pharmaceutical form,\n\n6. the content by weight, nominal volume or number of items,\n\n7. the method of administration,\n\n8. the active substances by type and quantity and other constituents by type insofar as this is imposed as a condition by the competent higher federal authority pursuant to section 28 (2) no. 1 or provided for by an ordinance pursuant to section 12 (1) no. 4, also in conjunction with subsection (2), or pursuant to section 36 (1); in the case of medicinal products intended for parenteral or topical use, including application to the eye, all constituents by type,\n\n8a. in the case of medicinal products manufactured using genetic engineering, the active substance and the name of the genetically modified organism or the cell line used in manufacture,\n\n9. the expiry date with the indication ‘verwendbar bis’ (to be used by) or with the abbreviation ‘verw. bis’,\n\n10. in the case of medicinal products that may only be dispensed upon prescription pursuant to section 48, the indication ‘Verschreibungspflichtig’ (prescription-only), in the case of other medicinal products that may only be dispensed to customers in pharmacies, the indication ‘Apothekenpflichtig’ (pharmacy-only),\n\n11. in the case of samples, the indication ‘unverkäufliches Muster’ (sample – not for sale).\n\n12. the indication that medicinal products are to be kept out of the reach of children unless they are curative waters,\n\n13. where necessary, special precautions for the disposal of unused medicinal products or other special precautions to avoid hazards to the environment, and\n\n14. in the case of non-prescription medicinal products, the intended use.\n\nInsofar as the information pursuant to sentence 1 is also provided in another language, the information provided in that language must be identical. Furthermore, space should be provided to state the prescribed dose; this does not apply to the containers and ampoules referred to in subsection (8) sentence 3 and to medicinal products intended exclusively for use by members of the medical profession. Medicinal products that are manufactured using a homeopathic manufacturing procedure and are authorised pursuant to section 25, are to be additionally labelled so as to indicate their homeopathic nature. Additional information that is not stipulated by a regulation of the European Community or the European Union, or is already admissible pursuant to such a regulation, is permitted if it is linked to the use of the medicinal product, is important in providing health information to patients and is not inconsistent with the information referred to in section 11a.\n\n(1a) In derogation of subsection (1) sentence 1, the competent higher federal authority can, in individual cases and at the request of the authorisation holder, permit medicinal products to be placed on the market temporarily with labelling in a language other than German in the event of an impending or existing supply-relevant bottleneck. In such cases, the competent higher federal authority will ensure that the consumer is given appropriate access to the necessary product information.\n\n(1b) The name of the medicinal product is to be placed on the outer packaging in Braille as well. The other information specified in subsection (1) sentence 1 no. 2 on the pharmaceutical form and the group of persons for which the medicinal product is intended does not have to be written in Braille; this also applies if this information is contained in the name of the medicinal product. Sentence 1 does not apply to medicinal products that:\n\n1. are intended exclusively for use by members of the medical profession, or\n\n2. are placed on the market in containers with a nominal volume of not more than 20 millilitres or not more than 20 grams.\n\n(1c) The outer packaging of medicinal products is to bear safety features, as well as a device to indicate possible tampering with the outer packaging of the medicinal product, insofar as this required by Article 54a of Directive 2001/83/EC of the European Parliament and of the Council of 6 November 2001 on the Community Code Relating to Medicinal Products for Human Use (OJ L 311 of 28.11.2001, p. 67; L 239 of 12.8.2014, p.81), last amended by Regulation (EU) 2019/1243 (OJ L 198 of 25.7.2019, p.241) or stipulated on the basis of Article 54a of Directive 2001/83/EC.\n\n(2) Moreover, warnings, specific storage instructions for the consumer as well as storage instructions for experts are to be given, insofar as this is deemed necessary according to the current level of scientific knowledge or has been imposed as a condition by the competent higher federal authority pursuant to section 28 (2) no. 1 or provided for by ordinance.\n\n(3) In respect of sera, information on the type of living organism from which the sera were obtained and, in respect of virus vaccines, information about the host system that was used for the multiplication of the virus is to be indicated.\n\n(4) In the case of medicinal products included in the Register of Homeopathic Medicinal Products, instead of the information referred to in subsection (1) sentence 1 nos. 1 to 14 and apart from the clearly recognisable indication: ‘Homöopathisches Arzneimittel’ (homeopathic medicinal product), the following information is to be included:\n\n1. the type and quantity of the stocks and the degree of dilution; in this regard, symbols from the pharmacopoeias currently used officially should be utilised; the scientific name of the stock can be supplemented by an invented name,\n\n2. the name and address of the pharmaceutical entrepreneur and, if available, of his/her local representative,\n\n3. method of administration,\n\n4. expiry date; subsection (1) sentence 1 no. 9 and subsection (7) apply,\n\n5. pharmaceutical form,\n\n6. the content by weight, nominal volume or number of items,\n\n7. indication that medicinal products should be kept out of the reach of children, other special precautions for storage and warnings, including additional information for safe use if required or if stipulated in subsection (2),\n\n8. batch identification,\n\n9. registration number abbreviated to ‘Reg.-Nr.’ and the phrase ‘Registriertes homöopathisches Arzneimittel, daher ohne Angabe einer therapeutischen Indikation’ (registered homeopathic medicinal product, therefore no therapeutic indication stated),\n\n10. indication advising the user to seek medical advice if medical symptoms persist during the use of the medicinal product,\n\n11. in the case of medicinal products that may only be dispensed to customers in pharmacies, the indication ‘Apothekenpflichtig’ (pharmacy-only),\n\n12. in the case of samples, the indication ‘unverkäufliches Muster’ (sample – not for sale).\n\nSentence 1 applies accordingly to medicinal products exempted from registration pursuant to section 38 (1) sentence 3; subsection (1b) does not apply.\n\n(4a) In the case of traditional herbal medicinal products pursuant to section 39a, the following indication must also be included in addition to the information pursuant to subsection (1):\n\n1. the medicinal product is a traditional medicinal product registered for the therapeutic indication exclusively based on long-standing use, and\n\n2. if medical symptoms persist, or in the event of adverse reactions other than those referred to in the package leaflet, the user should consult a physician or other medically qualified person.\n\nThe information in subsection sentence 1 no. 3 is replaced by the registration number abbreviated to ‘Reg.-Nr.’.\n\n(5) (repealed)\n\n(6) The following applies to the designation of the constituents:\n\n1. in designating the type, the World Health Organization’s international non-proprietary names or, if such names do not exist, other common scientific names are to be used; the Federal Institute for Drugs and Medical Devices stipulates, in agreement with the Paul Ehrlich Institute, the names to be used and publishes these in a database pursuant to section 67a;\n\n2. in designating the amount, units of measure are to be used; if biological units or other particulars concerning the valency are scientifically common, they are to be used,\n\n(7) The expiry date is to be indicated by month and year.\n\n(8) Blister packaging is to bear the name or firm of the pharmaceutical entrepreneur, the name of the medicinal product, the batch identification and the expiry date. It is not necessary to indicate the name and firm of a parallel importer. In the case of containers with a nominal volume of not more than 10 millilitres and single-dose ampoules, the information specified in subsections (1), (2) to (5) need only be displayed on the outer packaging; the containers and the ampoules must, however, at least bear the information specified in subsection (1) sentence 1 no. 2 first half-sentence, nos. 4, 6, 7, 9 as well as pursuant to subsections (3) and (5) sentence 1 nos. 1, 3, 7, 9, 12 and 14; adequate abbreviations may be used. Sentence 3 also applies to small containers other than those mentioned therein insofar as divergent requirements are placed on small containers in procedures pursuant to section 25b.\n\n(8a) In the case of fresh plasma preparations and preparations of blood cells, at least the information specified in subsection (1) sentence 1 nos. 1 and 2 must be included, without stating the strength, pharmaceutical form and target group, no. 3 or the approval number with the abbreviation ‘Gen. Nr.’, nos. 4, 6, 7 and 9 as well as the name and volume of the anticoagulant and, if available, the additive solution, storage temperature, blood group and, in the case of allogenic preparations derived from red blood cells, the rhesus formula as well and, in the case of thrombocyte concentrates and autologous preparations from red blood cells, also the rhesus factor. In the case of autologous blood preparations, the information ‘Nur zur Eigenbluttransfusion’ (Only for Autologous Blood Donation) must also be given and, in the case of autologous and directed blood preparations, also an indication of the recipient. In the case of haematopoietic stem cell preparations made from peripheral blood or umbilical cord blood, the Single European Code with the abbreviation ‘SEC’ must be given, as well as the information ‘Biologische Gefahr’ (Biological Danger) in the event that infectivity has been detected.\n\n(8b) In the case of tissue preparations, at least the information pursuant to subsection (1) sentence 1 nos. 1 and 2, without stating the strength, pharmaceutical form and target group, no. 3 or the approval number with the abbreviation ‘Gen.Nr.’, nos. 4, 6 and 9 of the Single European Code with the abbreviation ‘SEC’ must be included, as well as the information ‘Biologische Gefahr’ (Biological Danger) in the event that infectivity has been detected. In the case of autologous tissue preparations, the information ‘Nur zur autologen Anwendung’ (Only for Autologous Use) must also be provided and, in the case of autologous and targeted tissue preparations, an additional indication as to the recipient.\n\n(9) Abbreviations customary in the medicinal product trade may be used in the indications given in compliance with subsections (1) to (5). The company to be indicated under subsection (1) no. 1 may be abbreviated, provided that the firm is generally recognisable from the abbreviation.\n\n(10) (repealed)\n\n(11) Partial amounts removed from finished medicinal products may only be dispensed with labelling that corresponds at least to the requirements stipulated in subsection (8) sentence 1. Subsection (1b) does not apply.\n\ntable of contents\n\nSection 10a\n\nLabelling of investigational and auxiliary medicinal products for clinical trials\n\n(1) Investigational and auxiliary medicinal products for clinical trials must be labelled in German.\n\n(2) Information that is also provided in another language must be identical in both language versions.\n\ntable of contents\n\nSection 11\n\nPackage leaflet\n\n(1) Finished medicinal products that are not intended for clinical trials and not exempted from the obligation to obtain a marketing authorisation pursuant to section 21 (2) nos. 1a, 1b or 3, may only be placed on the market within the purview of this Act with a package leaflet bearing the heading ‘Gebrauchsinformation’ (Instructions for Use) and containing, in the same order as below, in easily legible, readily comprehensible German and in conformity with the information referred to in section 11a:\n\n1. for the purpose of identifying the medicinal product:\n\na) the name of the medicinal product, section 10 (1) sentence 1 no. 2 applies accordingly,\n\nb) the substance or indication group or the mode of action;\n\n2. the therapeutic indications;\n\n3. a list containing information that must be known before the medicine is administered:\n\na) contra-indications,\n\nb) corresponding precautions when administering the medicinal product,\n\nc) interaction with other medicinal products or other products if this is likely to influence the effect of the medicinal product,\n\nd) warnings, especially if imposed as a condition by the competent higher federal authority pursuant to section 28 (2) no. 2 or based on section 7 of the Anti-Doping Act (Gesetz gegen Doping im Sport) or stipulated by ordinance pursuant to section 12 (1) no. 3;\n\n4. the instructions under normal conditions of use, relating to:\n\na) dosage,\n\nb) method of administration,\n\nc) frequency of administration, where necessary indicating the exact time when the medicinal product can or must be administered,\n\nas well as, where necessary, and according to the type of medicinal product:\n\nd) the duration of treatment, if this is meant to be stipulated,\n\ne) information in the event of overdosage, failure to take the medicine or on the risk of undesirable consequences if discontinued,\n\nf) the specific recommendation that a physician or pharmacist should be consulted in the event of queries relating to the use;\n\n5. relating to adverse reactions:\n\na) a description of the adverse reactions that can occur when the medicinal product is used as intended,\n\nb) the counter measures to be taken in the event of adverse reactions if required according to the current state of scientific knowledge, and\n\nc) a standard text that explicitly instructs the patient to inform their physicians, pharmacists, health professionals or the competent higher federal authority directly of every suspected adverse reaction whereby the report can be made in any – in particular also electronic – form;\n\n6. mention of the expiry date stated on the packaging and also:\n\na) a warning that the medicinal product may not be used after expiry of this date,\n\nb) if required, special precautions for storage and information on shelf life after opening of the container or after preparation of the ready-to-use preparation by the user,\n\nc) if required, a warning about specific visible signs indicating that the medicinal product may no longer be used,\n\nd) complete qualitative composition in terms of active substances and other constituents and quantitative composition in terms of the active substances, using the usual common names for each of the medicinal product’s pharmaceutical forms; section 10 (6) applies,\n\ne) the pharmaceutical form and content by weight, nominal volume or number of items for each of the medicinal product’s pharmaceutical forms,\n\nf) the name and address of the pharmaceutical entrepreneur and, if available, of his/her local representative,\n\ng) the name and address of the manufacturer or importer who released the finished medicinal product for placing on the market,\n\n7. in the case of a medicinal product known by other names in other Member States of the European Union and approved for placing on the market pursuant to Articles 28 to 39 of Directive 2001/83/EC, a list of the names approved in each Member State;\n\n8. the date of the last revision of the package leaflet.\n\nMedicinal products that are included on a list compiled pursuant to Article 23 of Regulation (EC) No. 726/2004 of the European Parliament and of the Council of 31 March 2004 laying down Union procedures for the authorisation and supervision of medicinal products for human use and establishing a European Medicines Agency (OJ L 136 of 30.4.2004, p. 138), last amended by Regulation (EU) 2019/5 (OJ L L4 f7.1.2019, p. 24), must, in addition, carry the following declaration: ‘Dieses Arzneimittel unterliegt einer zusätzlichen Überwachung’ (This medicinal product is subject to additional monitoring). This declaration must be preceded by a black symbol and be followed by an appropriate standardised explanatory text pursuant to Article 23 (4) of Regulation (EC) No. 726/2004. Explanatory information on the terms listed in sentence 1 is admissible. Insofar as information referred to in sentence 1 is also rendered on the package leaflet in another language, the information provided in this language must be identical. Sentence 1 does not apply to medicinal products that do not require a marketing authorisation pursuant to section 21 (2) no. 1. Additional information that is not stipulated by a regulation of the European Community or the European Union, or is already permissible pursuant to such a regulation, is permitted provided it relates to the use of the medicinal product, is important for the health education of patients and is not inconsistent with the information referred to in section 11a. With regard to the information referred to in sentence 1 no. 3 letters a to d, account is to be taken of the special situation of specific groups of persons such as children, pregnant women or nursing mothers, the elderly or persons with specific diseases, insofar as this is deemed necessary in the light of the current level of scientific knowledge; furthermore, where necessary, the effects that the use of the medicinal product could have on a person’s ability to drive or to operate specific machines should also be indicated. The marketing authorisation holder is required to keep scientifically up-to-date the package leaflet that includes the conclusions of assessments and recommendations published on the European internet portal set up pursuant to Article 26 of Regulation (EC) No. 726/2004.\n\n(1a) A sample of the package leaflet and modified versions must be sent to the competent higher federal authority unless the medicinal product is exempted from the obligation to obtain a marketing authorisation or registration.\n\n(1b) The standard texts required pursuant to subsection (1) sentence 1 no. 5 and sentence 3 are published by the competent higher federal authority in the Federal Gazette.\n\n(1c) In derogation of subsection (1) sentence 1, the competent higher federal authority can, in individual cases and at the request of the authorisation holder, permit medicinal products to be placed on the market temporarily with a package leaflet in a language other than German in the event of an impending or existing supply-relevant bottleneck. In such cases, the competent higher federal authority will ensure that the consumer is given appropriate access to the necessary product information.\n\n(2) Furthermore, the package leaflet must contain references to constituents, the knowledge of which is necessary for the safe and effective use of the medicinal product, as well as specific storage instructions for the consumer insofar as this is deemed necessary according to the current level of scientific knowledge or if imposed as a condition by the competent higher federal authority pursuant to section 28 (2) no. 2, or provided for by ordinance.\n\n(2a) In the case of radiopharmaceuticals, subsection (1) applies accordingly with the proviso that the precautions that are to be taken by the user and the patient in the preparation and administration of the medicinal product, as well as special precautions for the disposal of the containers used for transport and for the disposal of medicinal products that are not used, are taken.\n\n(3) In the case of medicinal products included in the register of homeopathic medicinal products, subsection (1) applies accordingly with the proviso that the information stipulated in section 10 (4), with the exception of the batch identification, the expiry date and the indication stipulated for samples, is included, as well as the name and address of the manufacturer who released the finished medicinal product for placing on the market, where this person is not the pharmaceutical entrepreneur. Sentence 1 applies accordingly to medicinal products that are exempted from registration pursuant to section 38 (1) sentence 3.\n\n(3a) In the case of sera, subsection (1) applies accordingly with the proviso that the type of living organism from which they are derived and, in the case of virus vaccines, the host system used for virus multiplication and, in the case of medicinal products derived from human blood plasma for fractionation, the country of origin of the blood plasma should be stated.\n\n(3b) In the case of traditional herbal medicinal products pursuant to section 39a, (1) applies accordingly with the proviso that the information referred to in subsection (1) sentence 1 no. 2 must state that the medicinal product is a traditional medicinal product registered for the specific therapeutic indication exclusively on the basis of long-standing use. In addition, the package leaflet should include the advice referred to in section 10 (4a) sentence 1 no. 2.\n\n(3c) The marketing authorisation holder must ensure that at the request of patients’ organisations, the package leaflet is made available in formats appropriate for the blind and partially-sighted persons.\n\n(3d) In the case of spa-waters, notwithstanding the requirements referred to in subsection (2), the information referred to in subsection (1) sentence 1 no. 3 letter b no. 4 letters e and f no. 5, provided that the information stated therein is stipulated, and no. 6 letter c, can be omitted. Furthermore, in the case of spa-waters, the order stipulated in subsection (1) is not compulsory.\n\n(4) (repealed)\n\n(5) Should it not be possible to provide the information stipulated in subsection (1) sentence 1 no. 3 letters a and c as well as no. 5, the indication ‘keine bekannt’ (none known) must be given. Should additional information be given on the package leaflet, it must be clearly set out and well separated from the information specified in subsections (1) to (3).\n\n(6) The package leaflet may be omitted provided that the information specified in subsections (1) to (3) is to be found either on the container or on the outer packaging. Subsection (5) applies accordingly.\n\n(7) Partial amounts removed from finished medicinal products may only be dispensed together with a copy of the package leaflet prescribed for the finished medicinal product. Subsection (6) sentence 1 applies accordingly. By way of derogation from sentence 1, in the case of the regular dispensing of partial amounts removed from finished medicinal products and dispensed in new, customised patient blisters in the context of long-term medication, copies of the package leaflet prescribed for the specific finished medicinal product must only be inserted if they have been modified compared with those previously inserted.\n\ntable of contents\n\nSection 11a\n\nExpert information\n\n(1) For finished medicinal products that are subject to or exempt from the obligation to obtain a marketing authorisation and released for trade outside of pharmacies, the pharmaceutical entrepreneur is obliged to make instructions for use by experts (expert information) available upon request to the following persons:\n\n1. physicians, dentists, veterinarians, pharmacists, as well as\n\n2. other persons practising medicine or dentistry professionally, if the medicinal products are not subject to prescription.\n\nThe instructions for expert use must carry the heading ‘Fachinformation’ (expert information) and include the following information written in clearly legible type in conformity with the Summary of Product Characteristics approved within the framework of the marketing authorisation, and in the following order:\n\n1. the name of the medicinal product followed by the strength and the pharmaceutical form;\n\n2. information on the qualitative and quantitative composition in terms of active substance and other constituents, knowledge of which is required for proper administration of the product, with the usual common or chemical name indicated; section 10 (6) applies;\n\n3. pharmaceutical form,\n\n4. clinical particulars:\n\na) therapeutic indications;\n\nb) dosage and method of administration for adults and, insofar as the medicinal product is indicated for administration to children, for children,\n\nc) contra-indications,\n\nd) special warnings and precautions for use, and in the case of immunological medicinal products, any special precautions to be taken by persons coming into contact with and administering these medicinal products to patients, together with any precautions to be taken by the patient, if required as a result of conditions imposed by the competent higher federal authority pursuant to section 28 (2) no. 1 letter a, or stipulated by section 7 of the Anti-Doping Act, or by an ordinance,\n\ne) interaction with other medicinal products or other products if this is likely to influence the effect of the medicinal product,\n\nf) use during pregnancy and nursing,\n\ng) effects on ability to drive or operate machinery,\n\nh) adverse reactions when used as intended,\n\ni) overdosage: symptoms, emergency response measures, antidote;\n\n5. pharmacological properties:\n\na) pharmacodynamic properties,\n\nb) pharmacokinetic properties,\n\nc) preclinical safety data;\n\n6. pharmaceutical particulars:\n\na) list of the other constituents,\n\nb) main incompatibilities,\n\nc) shelf life and where necessary, the shelf life on manufacturing a ready-to-use preparation of the medicinal product or after first opening the container,\n\nd) special precautions for storage;\n\ne) type and content of the container,\n\nf) special precautions for disposal of an opened medicinal product, or waste materials derived from it, in order to avoid any risk to the environment;\n\n7. marketing authorisation holder;\n\n8. marketing authorisation number;\n\n9. the date of first authorisation or extension of the authorisation;\n\n10. the date of revision of the expert information.\n\nThe expert information is to contain a standard text that explicitly calls upon health professionals to report every suspected adverse reaction to the competent higher federal authority whereby the report may take any – in particular also electronic – form. Medicinal products that are included on a list compiled pursuant to Article 23 of Regulation (EC) No. 726/2004 must, in addition, carry the following declaration: ‘Dieses Arzneimittel unterliegt einer zusätzlichen Überwachung’ (This medicinal product is subject to additional monitoring). This declaration must be preceded by a black symbol and be followed by an appropriate standardised explanatory text pursuant to Article 23 (4) of Regulation (EC) No. 726/2004.\n\nAdditional information that is not stipulated by a regulation of the European Community or the European Union, or is already permissible pursuant to such a regulation is permitted if it relates to the use of the medicinal product and is not inconsistent with the information referred to in sentence 2; such information must be clearly separate and distinct from the information referred to in sentence 2. Sentence 1 does not apply to medicinal products that do not require a marketing authorisation pursuant to section 21 (2) or are manufactured according homeopathic procedures. The marketing authorisation holder is required to keep scientifically up-to-date the expert information, which includes the conclusions of assessments and recommendations published on the European internet portal set up pursuant to Article 26 of Regulation (EC) No. 726/2004. The standard texts required pursuant to sentences 3 and 5 are published by the competent higher federal authority in the Federal Gazette.\n\n(1a) In the case of sera, the type of living organism from which they are derived, in the case of virus vaccines, the host system used for virus multiplication and, in the case of medicinal products derived from human blood plasma for fractionation, the country of origin of the blood plasma must be indicated.\n\n(1b) In respect of radiopharmaceuticals, details of the internal radiation dosimetry, additional detailed instructions for the extemporaneous preparation and the quality control of this preparation must also be given and, where necessary, the maximum storage time must also be indicated during which an intermediate preparation, such as an eluate or the medicinal product when ready for use, corresponds to its specifications.\n\n(1c) In the case of medicinal products available only on prescription pursuant to section 48, the information ‘Verschreibungspflichtig’ (prescription only) should also be added, for narcotic drugs the information ‘Betäubungsmittel’ (narcotic drugs), in the case of other medicinal products available to consumers only in pharmacies, the information ‘Apothekenpflichtig’ (pharmacy only); in the case of medicinal products containing a substance or a preparation pursuant to section 48 (1) sentence 1 no. 2 corresponding information must be given.\n\n(1d) For marketing authorisations of medicinal products pursuant to section 24b, the information referred to in subsection (1) relating to therapeutic indications, dosages or other objects of a patent can be omitted if it is still covered by patent law at the time of placing on the market.\n\n(2) The pharmaceutical entrepreneur is obliged to make all modifications to the expert information that are relevant for therapy accessible to the experts in an appropriate form. Where necessary, the competent higher federal authority may, by imposition of a condition, stipulate the form in which the changes are to be made accessible to all or to certain groups of experts.\n\n(3) A sample of the expert information and revised versions thereof must be sent immediately to the competent higher federal authority unless the medicinal product is exempted from the obligation to obtain a marketing authorisation.\n\n(4) The obligations referred to in subsection (1) sentence 1 can also be fulfilled in the case of medicinal products that are administered exclusively by members of the health professions by including the information referred to in subsection (1) sentence 2 in the package leaflet. The package leaflet must be headed with the title ‘Gebrauchsinformation und Fachinformation’ (instructions for use and expert information).\n\ntable of contents\n\nSection 12\n\nEmpowerment in respect of labelling, package leaflet and package sizes\n\n(1) The Federal Ministry is hereby empowered, in agreement with the Federal Ministry for Economic Affairs and Energy by ordinance subject to the approval of the Bundesrat:\n\n1. to extend the provisions of sections 10 and 11a to cover other medicinal products and to extend the expert information to include further details,\n\n2. to stipulate that the information indicated in sections 10 and 11 is to be made known to the consumer in another way,\n\n3. to stipulate that, for certain medicinal products or certain groups of medicinal products, warnings, warning symbols or recognition marks must be contained in or affixed to:\n\na) the containers, the outer packaging or the package leaflet or\n\nb) the expert information,\n\n4. to stipulate that specific constituents are to be listed by type on the containers and outer packaging or that attention should be drawn to them in the package leaflet,\n\nif this is deemed necessary in order to ensure the proper handling and proper administration of medicinal products within the purview of this Act and in order to prevent any direct or indirect risk to human health that could occur as a result of inadequate information.\n\n(1a) Furthermore, the Federal Ministry is hereby empowered to allow, by ordinance subject to the approval of the Bundesrat, the use of summarising names for substances or preparations from substances in the information provided on containers and outer packaging or in package leaflets or in expert information, as long as active constituents are not involved and no direct or indirect hazard to human health arising from inadequate of information is to be feared.\n\n(1b) Furthermore, the Federal Ministry is hereby empowered, in agreement with the Federal Ministry for Economic Affairs and Energy, by means of an ordinance subject to the approval of the Bundesrat to regulate:\n\n1. the labelling of starting materials intended for the manufacture of medicinal products, and\n\n2. the labelling of medicinal products that are intended for clinical trials and do not fall within the scope of Regulation (EU) No 536/2014,\n\nif this is necessary to prevent any direct or indirect risk to human health that could occur as a result of inadequate labelling.\n\n(2) The ordinance pursuant to subsection (1), (1a) or (1b) must be issued in agreement with the Federal Ministry for the Environment, Nature Conservation and Nuclear Safety in the case of radiopharmaceuticals and medicinal products in the manufacture of which ionising radiation is used or where, in the cases provided for in subsection (1) no. 3, warnings, warning symbols or recognition marks with regard to the information stipulated in section 10 (1) sentence 1 no. 13 or subsection (5) sentence 1 no. 10, section 11 (4) sentence 1 no. 9 or section 11a, (1) sentence 2 no. 6 letter f are required.\n\n(3) Furthermore, the Federal Ministry is hereby empowered to stipulate, by ordinance not subject to the approval of the Bundesrat, that medicinal products may only be placed on the market in specific package sizes and that they must be labelled accordingly by the pharmaceutical entrepreneur on the container or, if used, on the outer packaging. The fixing of these package sizes is done for specific active substances and takes into account the therapeutic indications, the duration of application and the pharmaceutical form. In fixing the package size, the following trisection is, in principle, to be used as a basis:\n\n1. packages for a short duration of application or tolerance tests,\n\n2. packages for an intermediate duration of application,\n\n3. packages for a relatively extended duration of application.\n\ntable of contents\n\nDivision 3\n\nManufacture of medicinal products\n\ntable of contents\n\nSection 13\n\nManufacturing authorisation\n\n(1) Any person who manufactures:\n\n1. medicinal products,\n\n2. (repealed),\n\n3. active substances that are of human, animal or microbial origin or are manufactured using genetic engineering, or\n\n4. other substances of human origin intended for the manufacture of medicinal products,\n\non a commercial or professional basis requires a permit by the competent authority. The same applies to legal persons, to associations that have not achieved the status of legal persons by being registered in the register of associations, and to business partnerships that manufacture medicinal products for distribution to their members. Sentence 1 applies accordingly to a trial on the basis of which the release of the medicinal product is explained. This is without prejudice to section 14 (4).\n\n(1a) Subsection (1) does not apply to:\n\n1. tissues within the meaning of section 1a no. 4 of the Transplantation Act that require a permit pursuant to section 20b or 20c,\n\n2. the collection and the laboratory tests of autologous blood for the manufacture of biotechnologically processed tissue products that require a permit pursuant to section 20b,\n\n3. tissue preparations that require a permit pursuant to section 20c,\n\n4. reconstitution, insofar as it does not concern medicinal products that are intended for use in clinical trials outside of the scope of Regulation (EU) No 536/2014.\n\n(2) The following does not require an authorisation pursuant to subsection (1):\n\n1. the owner of a pharmacy manufacturing medicinal products within the scope of the normal operation of a pharmacy, reconstituting or packaging including the labelling of medicinal products intended for clinical trials outside of the scope of Regulation (EU) No 536/2014 insofar as this corresponds to the trial protocol,\n\n2. the body responsible for a hospital, insofar as it is authorised to distribute medicinal products pursuant to the Pharmacies Act, reconstituting or packaging including the labelling of medicinal products intended for clinical trials outside of the scope of Regulation (EU) No 536/2014 insofar as this corresponds to the trial protocol,\n\n2a. the pharmacy for the activities mentioned in Article 61 (5) of Regulation (EU) No 536/2014,\n\n3. (repealed)\n\n4. the wholesaler for:\n\na) the decanting of liquefied oxygen into small portable containers for individual patients in hospitals or in physicians’ practices including the required labelling,\n\nb) decanting, packaging or labelling other medicinal products without altering them, provided the packages concerned are not intended for direct distribution to the consumer,\n\n5. the retailer who, in possession of the expert knowledge defined in section 50, decants, packages or labels medicinal products without altering them for direct distribution to the consumer,\n\n6. the manufacturer of active substances that are intended for use in the manufacture of medicinal products, which are manufactured using a procedure described in the homeopathic section of the Pharmacopoeia.\n\n(2a) The exceptions specified in subsection (2) nos. 1, 2 and 4 to 6 do not apply to the manufacture of blood preparations, tissue preparations, sera, vaccines, allergens, advanced therapy medicinal products, xenogeneic medicinal products and radiopharmaceuticals. Sentence 1 does not apply to the facilities specified in subsection (2) no. 1 or 2 insofar as\n\n1. the decanting in an unchanged form for an individual patient, packaging or labelling of sera of non-human or non-animal origin authorised for marketing within the purview of this Act, or\n\n2. the reconstitution or the packaging or labelling of medicinal products intended for clinical trials outside of the scope of Regulation (EU) No 536/2014 insofar as this corresponds to the trial protocol, or\n\n3. the manufacture of test allergens\n\nare concerned. The competent authority is to be notified of activities pursuant to sentence 2 nos. 1 and 3.\n\n(2b) Furthermore, an authorisation pursuant to subsection (1) is not required by a person who is a physician, dentist or otherwise authorised to practise medicine on human beings insofar as the medicinal products are manufactured directly under his/her professional responsibility for personal use by a specific patient. Sentence 1 does not apply to:\n\n1. advanced therapy medicinal products and xenogeneic medicinal products,\n\n2. medicinal products intended for clinical trials if it is not merely a case of reconstitution, as well as\n\n3. medicinal products that are subject to prescription pursuant to section 48, insofar as the manufacturer pursuant to sentence 1 is neither a physician nor a dentist.\n\n(2c) (repealed)\n\n(3) An authorisation issued pursuant to subsection (1) concerning the decanting of liquefied medicinal gases into the delivery receptacle of a tanker truck also covers the decanting of liquefied medicinal gases, without altering them, from a delivery receptacle of a tanker truck into containers installed at a hospital or on the premises of other consumers.\n\n(4) The decision on the granting of the authorisation is taken by the competent authority of the federal Land where the factory site is situated or is to be situated. As far as blood products, tissue preparations, sera, vaccines, allergens, advanced therapy medicinal products, xenogeneic medicinal products, medicinal products manufactured using genetic engineering as well as active substances and other substances intended for the manufacture of medicinal products and which are of human, animal or microbial origin or are manufactured using genetic engineering are concerned, the decision on the authorisation is reached in consultation with the competent higher federal authority.\n\n(5) The authorisation to manufacture investigational or auxiliary medicinal products within the meaning of Article 2 (2) nos. 5 and 8 of Regulation (EU) No. 536/2014 will be issued by the competent authority in accordance with Article 61 (1) to (3) of Regulation (EU) No 536/2014. Sections 16, 17 and 64 (3a) sentence 2 apply accordingly to the granting of the authorisation.\n\n(6) The holder of the authorisation pursuant to Section 5 must make it possible for the qualified person pursuant to section 14 (1) no. 1 and section 15 to discharge his/her duties and must place, in particular, all of the necessary technical aids at his/her disposal.\n\ntable of contents\n\nSection 14\n\nDecision on the manufacturing authorisation\n\n(1) The authorisation may only be refused if:\n\n1. there is not at least one person available with the expert knowledge required pursuant to section 15 (qualified person pursuant to section 14) who is responsible for the activity referred to in section 19,\n\n2. (no longer applicable),\n\n3. the qualified person pursuant to no. 1 or the applicant is not sufficiently reliable in the performance of his/her job,\n\n4. the qualified person pursuant to no. 1 is unable to permanently meet the obligations incumbent on him/her,\n\n5. the physician under whose responsibility the pre-treatment of the donor for the purpose of separating haematopoietic stem cells from peripheral blood or other blood components is conducted does not possess the necessary expert knowledge,\n\n5a. in breach of section 4 sentence 1 no. 2 of the Transfusion Act (Transfusionsgesetz), no physician in charge has been appointed or said person does not possess the necessary professional knowledge according to the latest standards prevailing in medical science or, in breach of section 4 sentence 1 no. 3 of the Transfusion Act, no physician is present when the withdrawal procedure is carried out on a human donor,\n\n6. suitable premises and equipment for the intended manufacture, testing and storage of the medicinal products are not available, or\n\n6a. the manufacturer is unable to guarantee that the manufacture or testing of the medicinal products is conducted according to the latest standards prevailing in science and technology and, in the collection of blood and blood components, additionally according to the provisions of Division 2 of the Transfusion Act.\n\n(2) (no longer applicable)\n\n(2a) The physician in charge pursuant to section 4 sentence 1 no. 2 of the Transfusion Act can also be the qualified person pursuant to subsection (1) no. 1.\n\n(2b) (no longer applicable)\n\n(3) (no longer applicable)\n\n(4) By way of derogation from subsection (1) no. 6, it is possible to conduct partly outside of the manufacturer’s factory site:\n\n1. the manufacture of medicinal products for clinical trials at a commissioned pharmacy,\n\n2. the changing of the expiry date of medicinal products for clinical trials at a trial site by a person commissioned by the manufacturer, insofar as these medicinal products are exclusively intended for use at this trial site,\n\n3. the testing of medicinal products at commissioned enterprises,\n\n4. the collection or testing, including laboratory testing of the donor samples of substances of human origin intended for the manufacture of medicinal products, with the exception of tissues, in other enterprises or facilities,\n\nwhich require no authorisation of their own, on condition that they have the premises and equipment suitable for this purpose and it is guaranteed that the manufacture and testing are carried out according to the latest standards prevailing in science and technology and the qualified person pursuant to subsection (1) no. 1 is able to assume his/her responsibilities.\n\n(5) Should there be any objections to the submitted documents, the applicant is to be given an opportunity to correct the flaws within an appropriate period of time. If the flaws are not corrected, the authorisation is to be refused.\n\ntable of contents\n\nSection 15\n\nExpert knowledge\n\n(1) Proof of the required expert knowledge on the part of the qualified person referred to in section 14 is furnished by:\n\n1. the licence to practise as a pharmacist, or\n\n2. the certificate testifying to the successful completion of a course of university studies in pharmacy, chemistry, pharmaceutical chemistry and technology, biology, human or veterinary medicine of at least four years’ duration,\n\nas well as a period of at least two years’ practical experience in the field of the qualitative and quantitative analysis and other quality testing of medicinal products or veterinary medicinal products. The minimum duration of the university studies can be three and a half years if studies are followed by theoretical and practical training of at least one year, which includes an internship of at least six months at a public pharmacy and is completed with a university-level examination. The duration of the practical experience pursuant to sentence 1 can be reduced by one year if the university studies are of at least five years’ duration and by one and a half years if the university studies are of at least six years’ duration. Where two university courses or two courses recognised as equivalent co-exist and where one of these extends over four years and the other over three years, it is to be assumed that the certificate awarded on completion of the university course or its recognised three-year equivalent is considered to fulfil the condition of duration referred to in sentence 2, insofar as the certificates awarded on completion of both courses are recognised as equivalent.\n\n(2) In the cases specified in subsection (1) no. 2, proof must be furnished to the competent authority that the university studies comprised theoretical and practical instruction at least in the following basic subjects and that an adequate knowledge exists thereof:\n\nexperimental physics\n\ngeneral and inorganic chemistry\n\norganic chemistry\n\nanalytical chemistry\n\npharmaceutical chemistry\n\nbiochemistry\n\nphysiology\n\nmicrobiology\n\npharmacology\n\npharmaceutical technology\n\ntoxicology\n\npharmaceutical biology.\n\nThe theoretical and practical instruction and sufficient knowledge may also be acquired at a university upon completion of university studies within the meaning of subsection (1) no. 2 and may be proved by examination.\n\n(3) Subsection (2) does not apply to the manufacture and testing of blood preparations, sera of human or animal origin, vaccines and allergens. In place of the evidence of practical experience required in subsection (1), proof must be furnished of at least three years’ experience in the field of medical serology or medical microbiology. By way of derogation from sentence 2, in place of the practical experience required in subsection (1), proof must be furnished of:\n\n1. at least three years’ experience in manufacture or testing in plasma processing enterprises with a manufacturing authorisation, in addition to at least six months’ experience in the field of transfusion medicine or medical microbiology, virology, hygiene or analytic procedure, in the case of blood preparations produced from blood plasma for the purpose of fractionation,\n\n2. at least two years’ experience in the field of transfusion medicine covering all the areas of manufacture and testing in the case of blood preparations made from blood cells and preparations made from fresh plasma as well as in the case of substances and blood components for the manufacture of blood preparations,\n\n3. at least six months’ experience in transfusion medicine or one year’s experience in the manufacture of autologous blood preparations in the case of autologous blood preparations,\n\n4. for haematopoietic stem cell preparations made from peripheral blood or umbilical cord blood, in addition to sufficient knowledge, at least two years’ experience in this field of activity especially in the technology on which it is based.\n\nWith regard to the pre-treatment of patients for the purpose of separating haematopoietic stem cells from peripheral blood or from other blood components, the physician responsible must provide evidence of sufficient knowledge in addition to at least two years’ experience in this or another, comparably qualifying field of activity. The prerequisites contained in subsection (1) remain valid for packaging and labelling.\n\n(3a) Subsection (2) does not apply to the manufacturing and testing of advanced therapy medicinal products, xenogeneic medicinal products, tissue preparations, medicinal products for use in in-vivo diagnosis by means of marker genes, tissue preparations, radiopharmaceuticals and active substances. In place of the practical experience required in subsection (1), proof must be furnished of:\n\n1. in the case of gene therapy medicinal products and medicinal products for use in in-vivo diagnosis by means of marker genes, at least two years’ experience in a medically relevant field, in particular of genetic engineering, microbiology, cell biology, virology or molecular biology,\n\n2. in the case of somatic cell therapy medicinal products and biotechnologically processed tissue products, at least two years’ experience in a medically relevant field, in particular of genetic engineering, microbiology, cell biology, virology or molecular biology,\n\n3. in the case of xenogeneic medicinal products, at least three years’ experience in a medically relevant field including at least two years’ activity particularly in one of the fields mentioned under no. 1,\n\n4. in the case of tissue preparations, at least two years’ experience in the manufacture and testing of such medicinal products in enterprises and facilities that require a manufacturing authorisation pursuant to this Act or possess a manufacturing authorisation under European Union legislation,\n\n5. in the case of radiopharmaceuticals, at least three years’ experience in the field of nuclear medicine or that of radiopharmaceutical chemistry, and,\n\n6. in the case of active substances other than those listed under subsection (3) sentence 3 no. 2, at least two years’ experience in the manufacture and testing of active substances.\n\n(4) The period of practical experience specified in subsection (1) must be spent at a firm which has been granted a manufacturing authorisation by a Member State of the European Union, by another State Party to the Agreement on the European Economic Area or by a state with which an agreement exists as to the mutual recognition of certificates pursuant to section 72a sentence 1 no. 1.\n\n(5) (repealed)\n\n(6) A legally exercised function as a qualified person, subsequent to an examination of the necessary expert knowledge by the competent authority, also entitles a person to exercise this function within the remit of another competent authority, unless there are substantiated grounds to suppose that the existing expert knowledge is insufficient for the new function.\n\ntable of contents\n\nSection 16\n\nLimitation of the manufacturing authorisation\n\nThe authorisation is issued to the applicant for a specific factory site and for particular medicinal products and pharmaceutical forms of medicinal products and, in cases as defined in section 14 (4), also for a specific factory site of the commissioned company or the other company. Insofar as the authorisation includes the testing of medicinal products or active substances, the type of testing is to be specified.\n\ntable of contents\n\nSection 17\n\nDeadlines for the granting of marketing authorisations\n\n(1) The competent authority must take the decision on the application for authorisation within a period of three months.\n\n(2) If the holder of the authorisation makes an application for the authorisation to be modified in respect of the medicinal products to be manufactured or the premises and equipment as defined in section 14 (1) no. 6, the authority must reach a decision within a period of one month. In exceptional cases, the deadline is extended by an additional two months. The applicant is to be notified thereof prior to the expiry of the deadline and notified of the grounds.\n\n(3) If the authority gives the applicant the opportunity to correct the flaws pursuant to section 14 (5), the deadlines are interrupted until such flaws have been corrected or until the expiry of the deadline set pursuant to section 14 (5). The interruption of the deadline begins on the day the applicant receives the request to correct the flaws.\n\ntable of contents\n\nSection 18\n\nWithdrawal, revocation, suspension\n\n(1) The authorisation is to be withdrawn if it becomes known subsequently that one of the grounds for refusal, pursuant to section 14 (1), existed at the time the authorisation was granted. The authorisation is to be revoked if one of the grounds for refusal subsequently developed; the suspension of the authorisation may be ordered instead of its revocation. Section 13 (4) applies accordingly.\n\n(2) The competent authority may issue a provisional order mandating that the manufacture of a medicinal product be discontinued if the manufacturer fails to furnish the evidence required for manufacture and testing. The provisional order may be restricted to one batch.\n\ntable of contents\n\nSection 19\n\nAreas of responsibility\n\nThe qualified person pursuant to section 14 is responsible for ensuring that each batch of the medicinal product is manufactured and tested in accordance with the regulations applicable to the trade in medicinal products. He/she must certify the fulfilment of these provisions for each batch of medicinal products in a serially numbered register or comparable document before it is placed on the market.\n\ntable of contents\n\nSection 20\n\nObligations to notify\n\nThe marketing authorisation holder must notify the competent authority in advance of any change in the information referred to in section 14 (1) and submit evidence. Any unforeseen change in the qualified person referred to in section 14 must be notified immediately.\n\ntable of contents\n\nSection 20a\n\nApplicability to active substances and other substances\n\nSection 13 (2) and (4) and sections 14 to 20 apply accordingly to active substances and to other substances of human origin intended for use in the manufacture of medicinal products, insofar as their manufacture or testing pursuant to section 13 (1) requires an authorisation.\n\ntable of contents\n\nSection 20b\n\nAuthorisation for the collection of tissues and the pertinent labo"
    }
}